INmune Bio Inc. (NASDAQ: INMB) Developing Novel Immunotherapies Targeting Alzheimer’s Disease, Cancer

May 30, 2019 09:14:28
  • INmune Bio is a diversified, clinical stage immunology company developing novel therapies targeting distinct parts of a patient’s innate immune system to fight disease
  • Drug candidates INKmune and INB03 may be used to treat cancer; XPro1595 targets neuroinflammation as a cause of Alzheimer’s disease
  • The company was awarded a $1 million “Part the Cloud” grant from the Alzheimer’s Association to advance XPro1595 research
  • INmune recently entered a common stock purchase agreement for up to $20 million with Lincoln Park Capital

INmune Bio Inc. (NASDAQ: INMB), an immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, is pursuing several drug candidates that utilize a precision therapy approach to treat unsolved problems in medicine. Among the company’s active drug candidates are INKmune and INB03, which may be used to treat cancer, and XPro1595, which targets neuroinflammation as a cause of Alzheimer’s disease (

INmune Bio recently posted its Q1 2019 financial results in a shareholder update, which highlighted the achievement of becoming the first biotechnology company to close an initial public offering (IPO) in 2019 and…

Read More>>

NOTE TO INVESTORS: The latest news and updates relating to INMB are available in the company’s newsroom at

About NetworkNewsWire 

NetworkNewsWire (NNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) NetworkNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

To receive instant SMS alerts, text STOCKS to 77948

For more information please visit

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published:

NetworkNewsWire (NNW)
New York, New York
212.418.1217 Office